Medical device maker RxSight beats Q3 revenue estimates , narrows 2025 revenue forecast

RxSight

05/11/2025 21:57

Overview

RxSight Q3 2025 revenue beats analyst expectations despite a 14% yr/yr decrease

Company's gross margin improves to 80%, driven by favorable product mix shift

RxSight narrows 2025 revenue guidance, raises gross margin outlook

Outlook

Company narrows 2025 revenue range to $125 mln-$130 mln

Company raises 2025 gross margin guidance to 76%-77%

Operating expenses projected to remain $145 mln-$155 mln

Result Drivers

LAL SALES INCREASE - LAL sales volume increased by 6% compared to Q3 2024, contributing positively to revenue despite overall decline

LDD SALES DECLINE - LDD sales decreased by 68%, significantly impacting overall revenue

GROSS MARGIN IMPROVEMENT - Gross margin increased to 80%, driven by a favorable shift in product mix towards LAL sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$30.30 mln
$25.30 mln (9 Analysts)
Q3 Gross Profit
$24.20 mln
Q3 Operating Expenses
$36.40 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 8 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Rxsight Inc is $9.00, about 0% even its November 4 closing price of $9.00

Press Release: ID:nGNX74swwK

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)